Artiva Biotherapeutics, Inc.

Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on developing natural killer (NK) cell-based therapies for autoimmune diseases and cancers. Its lead product candidate is AlloNK, an off-the-shelf NK cell therapy designed to treat conditions such as rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis, pemphigus vulgaris, anti-neutrophil cytoplasmic antibody-associated vasculitis, and B-cell non-Hodgkin lymphoma. Additionally, Artiva is developing AB-201, an allogeneic anti-HER2 CAR-NK cell therapy for solid tumors including breast, gastric, esophageal, and bladder cancers, and AB-205, an allogeneic anti-CD5 CAR-NK cell therapy for hematological malignancies. The company operates in the biotechnology industry within the healthcare sector.

Artiva Biotherapeutics, Inc. is listed on the Nasdaq Capital Market (NasdaqGM) under the ticker symbol ARTV. The company's stock is traded in US dollars (USD), reflecting its primary listing in the United States. As a Nasdaq-listed company, Artiva is subject to the reporting and governance requirements of the US Securities and Exchange Commission.

Artiva Biotherapeutics operates in the healthcare sector, specifically within the biotechnology industry. As a clinical-stage biotechnology company, it focuses on developing innovative cell-based therapies, particularly natural killer (NK) cell treatments, for autoimmune diseases and cancers. The biotechnology industry involves using living organisms or their components to develop therapeutic products, and Artiva's work in NK cell therapy represents a cutting-edge area of immuno-oncology and autoimmune disease treatment.

Artiva Biotherapeutics, Inc. is headquartered in San Diego, California, United States. The company primarily serves the US market, as indicated by its US-based operations and listing on the Nasdaq exchange. While its therapies target global health conditions such as autoimmune diseases and cancers, its clinical trials and regulatory focus are centered in the United States. The company was incorporated in 2019 and has since been advancing its pipeline of NK cell therapies for patients with unmet medical needs.

Artiva Biotherapeutics has three main product candidates in its pipeline. AlloNK is an off-the-shelf NK cell therapy targeting autoimmune diseases like rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis, pemphigus vulgaris, and ANCA-associated vasculitis, as well as B-cell non-Hodgkin lymphoma. AB-201 is an allogeneic anti-HER2 CAR-NK cell therapy for solid tumors including breast, gastric, esophageal, and bladder cancers. AB-205 is an allogeneic anti-CD5 CAR-NK cell therapy for hematological malignancies. These candidates are all in clinical-stage development, leveraging natural killer cells to attack diseased cells.